Braun Stacey Associates’s Biogen BIIB Stock Holding History

Braun Stacey Associates’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,269	Closed	-$370K	–	140
2015 Q3	$370K	Sell	1,269 -56,379	-98%	-$18.6M	0.02%	127
2015 Q2	$23.3M	Buy	57,648 +1,630	+3%	+$654K	0.99%	22
2015 Q1	$23.7M	Sell	56,018 -5,838	-9%	-$2.3M	1.39%	4
2014 Q4	$21M	Buy	61,856 +2,160	+4%	+$699K	1.28%	9
2014 Q3	$19.7M	Sell	59,696 -4,598	-7%	-$1.52M	1.22%	14
2014 Q2	$20.3M	Sell	64,294 -7,361	-10%	-$2.22M	1.21%	14
2014 Q1	$21.9M	Sell	71,655 -10,497	-13%	-$3.33M	1.28%	14
2013 Q4	$23M	Sell	82,152 -8,718	-10%	-$2.25M	1.31%	12
2013 Q3	$21.9M	Sell	90,870 -8,625	-9%	-$1.93M	1.35%	11
2013 Q2	$21.4M	Buy	+99,495	New	+$21.3M	1.35%	9

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Braun Stacey Associates's BIIB Position: Q4 2015 in Review

Braun Stacey Associates sold out of Biogen (BIIB) in Q4 2015, closing a stake of 1,269 shares — an estimated $370K sold.

Braun Stacey Associates first reported a position in BIIB in Q2 2013 and held it in 10 quarters. The position peaked at $23.7M in Q1 2015. 970 funds tracked by Wall St. Rank hold BIIB as of Q4 2015.

Braun Stacey Associates reported no remaining Biogen position as of Q4 2015 after selling out during the quarter.
Braun Stacey Associates sold 1,269 Biogen shares in Q4 2015, an estimated $370K.
Braun Stacey Associates first reported a position in Biogen in Q2 2013 and held it in 10 quarters.
Braun Stacey Associates's Biogen position peaked at $23.7M in Q1 2015.
970 funds tracked by Wall St. Rank held Biogen as of Q4 2015.

Based on Braun Stacey Associates's 13F filing for Q4 2015, filed 28 Jan 2016.